In a bid to round out its commercial offerings for detecting heart attack and stroke, Boston Heart Diagnostics (Framingham, Massachusetts) reported the commercial launch of an FDA-cleared MPO (myeloperoxidase) test, a key biomarker for inflammation. Studies show that MPO levels are useful predictors of near-term (one to six months) risk of heart attack or stroke.
Read More
